Posicor's removal from the market
July 1998
Posicor's removal from the market, less than a year after itwas approved, shows how hard it is to predict drug interactions.
Posicor inhibits cytochrome P450 enzymes that are important formetabolizing many other drugs. This can allow other drugs to buildup to toxic levels...or prevent the formation of active metabolites.
Posicor (mibefradil) can interact with more than 25 drugsincluding other calcium blockers...beta-blockers...erythromycin...lovastatin...digoxin...and quinidine.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote